2016-01-011 - βPFO - βPFO: A novel and promising new target against Alzheimer’s disease

βPFO

2016-01-011

New target in Alzheimer’s disease (AD). A methodology applicable as an in-vitro screening method for modulators of this target.

IRB Barcelona adheres to the 3 pillars of ESG, environmental, social and governance, to perform all of their projects with the highest standards

not applicable

Problem: About 17% of people over 60 show mild cognitive impairment, characterized by a slight but noticeable and measurable decline in cognitive abilities. These features lead to an increased risk of developing AD or another dementia. Nonetheless, AD is not a disease limited to older people, as up to 5% of people with this condition have early onset AD (also known as younger-onset AD), which often appears when someone is in their 40s or 50s. Solution: βPFO describes a new target in Alzheimer’s disease (AD) and a methodology applicable as an in-vitro screening method for modulators of this target. These modulators can then serve as the long-expected directed therapy for AD.

0

0

0

Licencing

Neurodegenerative disease with no effective cure.

Given the case the project is reactivated, new funding will be necessary to (i) validate the pore in-vivo and (ii) conduct a screening for modulators. This could generate new IPRights around the technology

New proposed mechanism of action to fight Alzheirmer's Disease.

Lack of IPR, need for further maturation in order to be commercially attractive

In case the project is resumed and new IP need to be generated in order to provide a business case.

Patent abandoned

Project currently abandoned.

Patents: WO2017162666A1 - PCT/EP2017/056688 - Date: Sep 28th, 2017 Status: Granted URL: https://patents.google.com/patent/WO2017162666A1/en

This target can serve as the long-expected directed therapy for AD, an unmet medical need affecting more than 44 million people worldwide and estimated to cost over €175 billion each year.